-
Subject Areas on Research
-
A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome.
-
A comparison of the fine saccharide-binding specificity of Dioclea grandiflora lectin and concanavalin A.
-
Antigen expression in xenotransplantation: how low must it go?
-
Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices.
-
Biophysical characteristics of anti-Gal(alpha)1-3Gal IgM binding to cell surfaces: implications for xenotransplantation.
-
Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection.
-
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
-
Diagnosis of Life-Threatening Alpha-Gal Food Allergy Appears to Be Patient Driven.
-
Differential recognition by proteins of alpha-galactosyl residues on endothelial cell surfaces.
-
Disaccharidase activities and fat assimilation in pediatric patients after intestinal transplantation.
-
Distribution of, and immune response to, chicken anti-alpha Gal immunoglobulin Y antibodies in wild-type and alpha Gal knockout mice.
-
Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia.
-
Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
-
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis.
-
Evidence for polyreactive xenoreactive antibodies in the repertoire of human anti-swine antibodies: the 'next' humoral barrier to xenotransplantation?
-
Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.
-
Galactose-α-1,3-galactose and delayed anaphylaxis, angioedema, and urticaria in children.
-
Glucose activates mitogen-activated protein kinase (extracellular signal-regulated kinase) through proline-rich tyrosine kinase-2 and the Glut1 glucose transporter.
-
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
-
Identifying adolescents at risk for depression: Assessment of a global prediction model in the Great Smoky Mountains Study.
-
Interaction of the Shiga-like toxin type 1 B-subunit with its carbohydrate receptor.
-
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.
-
Molecular barriers to xenotransplantation.
-
Relative purity of thrombin-based hemostatic agents used in surgery.
-
Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
-
Role of the microvillus in the absorption of disaccharides.
-
Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
-
Specificity and function of "natural" antibodies in immunodeficient subjects: clues to B cell lineage and development.
-
Structural adaptations that modulate monosaccharide, disaccharide, and trisaccharide specificities in periplasmic maltose-binding proteins.
-
The crystal structure of a thermophilic glucose binding protein reveals adaptations that interconvert mono and di-saccharide binding sites.
-
The footprint of antibody bound to pig cells: evidence of complex surface topology.
-
The humoral immune response in humans following ex vivo perfusion of porcine livers.
-
The potential of xenotransplants.
-
The role of anti-Galalpha1-3Gal antibodies in acute vascular rejection and accommodation of xenografts.
-
The role of natural anti-Gal alpha 1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants.
-
Using the galactose-α-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab.